The majority of cancer patients deal with mental disorders. Scientists now highlight the necessity of psychological support additional to treatment.
Stereotactic body radiotherapy (SBRT) can improve outcomes in patients with non-small cell lung cancer (NSCLC), according to new research.
Early palliative care improved the quality of life of patients with incurable cancer, lowering levels of depression, according to researchers.
A new study reveals that cancer caregivers face more stress and depression compared to other caregivers.
Patients with advanced non-clear cell renal cell carcinoma (ncRCC) benefited from the combination treatment of everolimus and bevacizumab, researchers report.
Advanced non-Hodgkin lymphoma ((NHL) patients receiving T-cell treatment, JCAR014 and chemotherapy had a complete response, new data show.
Key findings of the studies including ofatumumab, ponatinib, liposomal vincristine and reduced-intensity therapy for the treatment of ALL patients.
Promising results from treatment options for older patients with acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL).
Oropharyngeal cancer patients may avoid significant pain and disfigurement if treated with incisionless robotic surgery, a new study shows.
Many terminal cancer patients receive their pain relief drug prescription too late, a new research reveals.
A randomized trial proved the importance of joint decision making between prostate cancer patients and physicians during the treatment selection process.
Neoadjuvant chemotherapy followed by surgery led to better outcomes in pancreatic cancer compared to upfront surgery with or without adjuvant chemotherapy.
An expert panel issued recommendations on post-mastectomy radiation therapy for breast cancer patients, calling for careful counseling and clinical judgement.
The cardioprotective drug dexrazoxane may prevent the chemotherapy-related heart damage of children with cancer treated with anthracyclines, data reveal.
Similar quality of life for lung cancer patients with brain metastasis treated with whole brain radiotherapy compared to those who didn’t, an analysis shows.
Cancer patients treated with apixaban saw a 70% reduction in the composite endpoint of stroke, new findings show.
Half of female breast cancer survivors may suffer from chemo brain, a genuine consequence of chemotherapy. Study tries to find how long it is likely to last.
Venetoclax induced promising outcomes to acute myelogenous leukemia patients whose disease had relapsed or was resistant to chemotherapy, a trial shows.
Prostate cancer patients undergoing robotic surgery experienced similar quality of life compared to those undergoing open surgery, a trial reveals.
Obesity and smoking were associated with higher risk of developing cardiotoxicity after treatment in breast cancer patients, clinical studies reveal.
Metastatic brain cancer patients treated with stereotactic radiosurgery had less cognitive deterioration three months after treatment, a study finds.
Adding local peripheral treatments to systemic ipilimumab increased survival in melanoma patients, a retrospective analysis shows.
A study reveals that some adult advanced kidney cancer patients may safely opt for an active surveillance scheme instead of aggressive treatments.
US regulators approved pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Very high-risk prostate cancer patients treated with a high proportion of radical local treatment survived longer, according to a new study.
REVLIMID® (lenalidomide) received approval by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Hodgkin lymphoma patients remained disease-free for over five years after being treated with the immunotherapy brentuximab vedotin, new data shows.
Lenvatinib combined with everolimus received a positive opinion by the EU regulator for the treatment of adult patients with advanced renal cell carcinoma.
Treatment’s impact on quality of life should be considered when choosing treatment for head and neck squamous cell carcinoma, an analysis shows.
US regulator approved the marketing of a molecular diagnostic test measuring BCR-ABL levels in patients with chronic myeloid leukemia (CML).